keyword
MENU ▼
Read by QxMD icon Read
search

New treatment in HCV

keyword
https://www.readbyqxmd.com/read/28222681/the-need-for-treatment-scale-up-to-impact-hcv-transmission-in-people-who-inject-drugs-in-montr%C3%A3-al-canada-a-modelling-study
#1
Anthony Cousien, Pascale Leclerc, Carole Morissette, Julie Bruneau, Élise Roy, Viet Chi Tran, Yazdan Yazdanpanah, Joseph Cox
BACKGROUND: HCV transmission remains high in people who inject drugs (PWID) in Montréal. New direct-acting antivirals (DAAs), highly effective and more tolerable than previous regimens, make a "Treatment as Prevention" (TasP) strategy more feasible. This study assesses how improvements in the cascade of care could impact hepatitis C burden among PWID in Montréal. METHODS: We used a dynamic model to simulate HCV incidence and prevalence after 10 years, and cirrhosis complications after 10 and 40 years...
February 21, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/28218976/differential-expression-of-innate-immune-response-genes-in-clinical-phases-of-chronic-hepatitis-b-infection
#2
Sara Romani, Seyed Masoud Hosseini, Seyed Reza Mohebbi, Andre Boonstra, Afsaneh Sharifian
We investigated innate immune gene expression in clinical phases of Chronic Hepatitis B infection, including immune tolerant (IT); immune active (IA); inactive carrier (IC); and hepatitis B e antigen (HBeAg)-negative phases, as well as healthy controls. Expression levels of interferon types I, II, and III, their receptor subunits, IRFs, TLRs and other IFN-induced genes in peripheral blood mononuclear cells were compared.Forty HBsAg-positive treatment-naïve subjects without co-infection with HIV, HCV or HDV were enrolled...
February 20, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28217253/miliary-tuberculosis-infection-during-hepatitis-c-treatment-with-sofosbuvir-and-ledipasvir-plus-ribavirin
#3
Maria Pilar Ballester-Ferré, Fernando Martínez, Natalia Garcia-Gimeno, Francisco Mora, Miguel A Serra
Chronic hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. In the last 5 years, treatment for HCV infection has experienced a marked development. In 2014, the use of ledipasvir/sofosbuvir with or without concomitant weight-based ribavirin was approved with a very significant increase in the sustained virological response. However, new side effects have been associated. We report the first case of an HCV infected patient treated for 12 wk with the combination of sofosbuvir/ledipasvir plus ribavirin who developed a miliary tuberculosis (TB) infection while on therapy...
January 28, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28214386/management-and-prognosis-of-hcc-in-the-elderly-results-of-an-in-field-multicenter-cohort-study
#4
Mauro Borzio, Elena Dionigi, Alessandro Vitale, Angelo Rossini, Massimo Marignani, Fabio Fornari, Susanna Vicari, Ilario De Sio, Fabio Farinati, Emanuela Bertolini, Filippo Oliveri, Gioacchino Leandro, Giampiero Francica, Mario Mitra, Barbara Omazzi, Sergio Boccia, Andrea Salmi, Anna Toldi, Rodolfo Sacco
AIMS: This multicentre cohort study evaluated the role of aging on clinical characteristics, treatment allocation, and outcome of new HCCs, in clinical practice. MATERIAL AND METHODS: From September 2008, 541 patients aged > 70 years old (elderly group), and 527 ≤ 70 years old (non elderly group) with newly diagnosed HCC were consecutively enrolled in 30 Italian centres. Differences in clinical characteristics and treatment allocation between groups were described by a multivariable logistic regression model measuring the inverse probability weight to meet the elderly group...
February 18, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28210927/efficacy-and-safety-of-daclatasvir-plus-pegylated-interferon-alfa-2a-and-ribavirin-in-previously-untreated-hcv-subjects-coinfected-with-hiv-and-hcv-genotype-1-a-phase-iii-open-label-study
#5
Mark S Sulkowski, Walford J Fessel, Adriano Lazzarin, Juan Berenguer, Natalia Zakharova, Hugo Cheinquer, Pierre Côté, Douglas Dieterich, Adrian Gadano, Gail Matthews, Jean-Michel Molina, Christophe Moreno, Juan Antonio Pineda, Federico Pulido, Antonio Rivero, Jurgen Rockstroh, Dennis Hernandez, Fiona McPhee, Timothy Eley, Zhaohui Liu, Patricia Mendez, Eric Hughes, Stephanie Noviello, Peter Ackerman
BACKGROUND: Daclatasvir (DCV) is a potent, pangenotypic, hepatitis C virus (HCV) non-structural protein 5A inhibitor with low potential for drug interactions with antiretroviral therapy (ART). We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients. METHODS: AI444043 (NCT01471574), an open-label, Phase III, single-arm, response-guided treatment (RGT) study included 301 patients. They received DCV doses of 30, 60 or 90 mg once daily (depending on concomitant ART), plus weight-based RBV (<75 kg, 1000 mg/day; or ≥75 kg, 1200 mg/day), and once-weekly PegIFN 180 μg, for 24 weeks...
February 16, 2017: Hepatology International
https://www.readbyqxmd.com/read/28208098/-don-t-think-i-m-going-to-leave-you-over-it-accounts-of-changing-hepatitis-c-status-among-couples-who-inject-drugs
#6
Jake Rance, Carla Treloar, Suzanne Fraser, Joanne Bryant, Tim Rhodes
BACKGROUND: While the health-related benefits of intimate partnership are well documented, little attention has been paid to couples exposed to high levels of social stigma and exclusion. In this project we investigated an important site of stigma for partnerships by collecting accounts of changing hepatitis C (HCV) status ("sero-change") among couples that inject drugs. We explored what these accounts reveal about the meaning of HCV for these couples, and how this understanding contributes to our collective efforts at prevention and care...
January 31, 2017: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/28203449/a-cost-utility-analysis-of-different-antiviral-medicine-regimens-in-patients-with-chronic-hepatitis-c-virus-genotype-1-infection
#7
Seyed Moayed Alavian, Shekoufeh Nikfar, Abbas Kebriaeezadeh, Farhad Lotfi, Ehsan Sanati, Mohsen Rezaei Hemami, Khosro Keshavarz
BACKGROUND: Despite the introduction of new drug regimens with high effectiveness for the hepatitis C virus (HCV) patients, especially in HCV genotype 1, no cost-effectiveness study on the selection of the superior drug strategy in Iran has been conducted yet. OBJECTIVES: This study is aimed to assess the cost-effectiveness of the three drug regimens of pegylated interferon and ribavirin (PR), sofosbuvir (SOF) + PR and ledipasvir and sofosbuvir (LDV/SOF) in patients with HCV genotype 1 in Iran in the year 2014...
November 2016: Iranian Red Crescent Medical Journal
https://www.readbyqxmd.com/read/28193102/identification-of-predictors-for-treatment-failure-in-hepatitis-c-virus-patients-treated-with-ledipasvir-and-sofosbuvir
#8
Jeffrey W Jansen, Gillian M Powderly, Travis W Linneman
BACKGROUND: New hepatitis C virus (HCV) therapies report cure rates of ~90% but are expensive. Identification of predictors for treatment failure could help decrease health care costs, limit unnecessary drug exposure and adverse events, and prevent drug-drug interactions. Failure to achieve rapid viral response (RVR), defined as detectable viral load at 4 weeks, has previously been identified as a predictor of treatment failure with some previous HCV therapies. OBJECTIVE: To evaluate RVR, and other potential variables, as predictors of treatment failure in patients treated with ledipasvir and sofosbuvir (LDV/SOF)...
February 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28192185/hepatic-decompensation-is-the-major-driver-of-death-in-hcv-infected-cirrhotic-patients-with-successfully-treated-early-hepatocellular-carcinoma
#9
Giuseppe Cabibbo, Salvatore Petta, Marco Barbara, Simona Attardo, Laura Bucci, Fabio Farinati, Edoardo G Giannini, Giulia Negrini, Francesca Ciccarese, Gian Lodovico Rapaccini, Maria Di Marco, Eugenio Caturelli, Marco Zoli, Franco Borzio, Rodolfo Sacco, Roberto Virdone, Fabio Andrea Marra Mega, Filomena Morisco, Luisa Benvegnù, Antonio Gasbarrini, Gianluca Svegliati-Baroni, Francesco Giuseppe Foschi, Andrea Olivani, Alberto Masotto, Gerardo Nardone, Antonio Colecchia, Marcello Persico, Antonio Craxì, Franco Trevisani, Calogero Cammà
BACKGROUND & AIMS: A major problem in assessing the long-term outcome of HCV-infected cirrhotic patients with successfully treated Barcelona Clinic Liver Cancer (BCLC) A hepatocellular carcinoma (HCC) arises from the lack of models accounting for early changes during follow-up. AIM: of study is to estimate the impact on 5-year overall survival (OS) of early (occurring within 12 months after complete radiological response) time-dependents events (HCC recurrence or hepatic decompensation) in a large cohort of successfully treated HCC patients with HCV cirrhosis...
February 9, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28191032/safety-of-new-daas-for-chronic-hcv-infection-in-a-real-life-experience-role-of-a-surveillance-network-based-on-clinician-and-hospital-pharmacist
#10
A Nappi, A Perrella, P Bellopede, A Lanza, A Izzi, M Spatarella, C Sbreglia
BACKGROUND: Direct Antiviral Agents (DAAs) for HCV therapy represents a step ahead in the cure of chronic hepatitis C. Notwithstanding the promising results in several clinical trials, few data are available on adverse effects in real life settings. METHODS: We have evaluated 170 patients with persistent infection and on those eligible to treatment we have followed up them through a network managed by clinician and hospital pharmacist. RESULTS: According to our data we have found that 41% (32 out of 78) of enrolled patients experienced adverse reactions, of these 40% were in those under 65 years while 60% was in patients older than 65 years, SVR was achieved in 88% of the patients (including drop-out)...
2017: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/28183221/sofosbuvir-in-the-treatment-of-early-hcv-infection-in-hiv-infected-men
#11
Ahmed El Sayed, Zachary R Barbati, Samuel S Turner, Andrew L Foster, Tristan Morey, Douglas T Dieterich, Daniel S Fierer
BACKGROUND: There is an international epidemic of hepatitis C virus (HCV) infection among HIV-infected men who have sex with men. We previously showed that adding telaprevir to pegylated interferon (IFN) and ribavirin (RBV) both shortened treatment and increased the cure rate of early HCV in these men. Whether shortening treatment of early HCV using IFN-free regimens would be similarly successful has not yet been demonstrated. METHODS: We performed a pilot study of treatment with sofosbuvir (SOF) + RBV for 12 weeks in early genotype 1 HCV infection in HIV-infected men...
February 10, 2017: HIV Clinical Trials
https://www.readbyqxmd.com/read/28183063/real-life-experience-with-direct-acting-antivirals-agents-against-hepatitis-c-infection-in-elderly-patients
#12
Iria Rodríguez-Osorio, Purificación Cid, Luis Morano, Ángeles Castro, Marta Suárez, Manuel Delgado, Luis Margusino, Héctor Meijide, Berta Pernas, Andrés Tabernilla, José D Pedreira, Álvaro Mena, Eva Poveda
BACKGROUND: New direct-acting antivirals agents (DAAs) are very safe and well tolerated. OBJECTIVES: The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have co-morbidities and are on chronic medications. STUDY DESIGN: All HCV-infected patients over 65 years old in clinical follow-up at two Hospitals in Spain who initiated anti-HCV therapy were included (August 2012-October 2015). RESULTS: A total of 120 HCV mono-infected patients were recorded...
March 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28182613/news-on-viral-hepatitis-in-hiv-update-from-the-2016-gehep-conference
#13
Eva Poveda, Massimo Puoti, Miguel García-Deltoro, Juan A Pineda, Francisco Téllez, Rafael Granados, Luis Morano, Federico García
The II Conference of the Group for the Study of Viral Hepatitis (GEHEP) (29 September-1 October, Spain) updated epidemiological, diagnostic and treatment aspects on viral hepatitis. The conference was mostly focused on the latest news related to HCV infection, including the successes achieved since the implementation of direct-acting antiviral agents for HCV therapy, but also in the new, future challenges for a real HCV eradication. The scenario for chronic HCV infection has dramatically changed in the last two years and most patients have been cured after 12 weeks of therapy with minimal side effects...
January 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28182611/use-of-daclatasvir-in-hcv-hiv-coinfected-patients-in-a-real-life-setting
#14
Stefano Bonora, Massimo Puoti
The burden of HIV and HCV coinfection is estimated to affect 5-7 million people worldwide, with approximately 15-30% of people with HIV coinfected with HCV. The first oral direct-acting antivirals have shown to improve the response in patients with HIV/HCV coinfection, and more recently, other direct-acting antivirals that target various stages of the HCV life cycle have been developed, among them daclatasvir. The objective of this article is to examine recent clinical studies investigating the efficacy and safety of daclatasvir in comparison with other antiretroviral drugs, focusing on its efficacy in the coinfected HIV patient and real-life data...
January 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28173785/hcv-screening-in-a-cohort-of-hiv-infected-and-uninfected-homeless-and-marginally-housed-women-in-san-francisco-california
#15
Kimberly Page, Michelle Yu, Jennifer Cohen, Jennifer Evans, Martha Shumway, Elise D Riley
BACKGROUND: Hepatitis C virus (HCV) screening has taken on new importance as a result of updated guidelines and new curative therapies. Relatively few studies have assessed HCV infection in homeless populations, and a minority include women. We assessed prevalence and correlates of HCV exposure in a cohort of homeless and unstably housed women in San Francisco, and estimated the proportion undiagnosed. METHODS: A probability sample of 246 women were recruited at free meal programs, homeless shelters, and low-cost single room occupancy hotels in San Francisco; women with HIV were oversampled...
February 7, 2017: BMC Public Health
https://www.readbyqxmd.com/read/28170123/martinello-et%C3%A2-al-hcv-reinfection-incidence-among-individuals-treated-for-recent-infection
#16
Patrick Ingiliz
The development of all-oral direct-acting antiviral agents (DAA) has changed the management of patients infected with the hepatitis C virus (HCV). As these new treatments are safe and highly effective, most affected patients may have a chance for HCV cure, at least in those parts of the world where the costly drugs available. In industrialized countries, HCV infection has a comparatively low prevalence in the general population(1) . A higher prevalence and new infections are mainly seen in two specific subgroups: people who inject drugs (PWID) and HIV-positive men who have sex with men (MSM)...
February 7, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28168002/hepatitis-c-virus-seroprevalence-in-the-general-female-population-of-9-countries-in-europe-asia-and-africa
#17
Gary M Clifford, Tim Waterboer, Bolormaa Dondog, You Lin Qiao, Dimitri Kordzaia, Doudja Hammouda, Namory Keita, Nahid Khodakarami, Syed Ahsan Raza, Ang Tshering Sherpa, Witold Zatonski, Michael Pawlita, Martyn Plummer, Silvia Franceschi
BACKGROUND: New oral treatments with very high cure rates have the potential to revolutionize global management of hepatitis C virus (HCV), but population-based data on HCV infection are missing in many low and middle-income countries (LMIC). METHODS: Between 2004 and 2009, dried blood spots were collected from age-stratified female population samples of 9 countries: China, Mongolia, Poland, Guinea, Nepal, Pakistan, Algeria, Georgia and Iran. HCV antibodies were detected by a multiplex serology assay using bead-based technology...
2017: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/28166520/universal-sustained-viral-response-to-the-combination-of-ombitasvir-paritaprevir-ritonavir-and-dasabuvir-with-without-ribavirin-in-patients-on-hemodialysis-infected-with-hepatitis-c-virus-genotypes-1-and-4
#18
Soraya Abad, Almudena Vega, Eduardo Hernández, Evangelina Mérida, Patricia de Sequera, Marta Albalate, Nicolás Macías, Monica Milla, Juan M López-Gómez
BACKGROUND: Hepatitis C virus (HCV) infection is highly prevalent among patients on hemodialysis (HD) and is associated with poor prognosis. Treatment with interferon and ribavirin is poorly tolerated, and few data are available on the impact of new direct-acting antivirals (DAAs). This study was intended to analyze the efficacy and safety of treatment with a combination of ombitasvir/paritaprevir/ritonavir and dasabuvir with/without ribavirin in HCV-infected patients on HD from 3 hospitals...
January 7, 2017: American Journal of Nephrology
https://www.readbyqxmd.com/read/28165830/pharmacokinetic-drug-evaluation-of-velpatasvir-plus-sofosbuvir-for-the-treatment-of-hepatitis-c-virus-infection
#19
Teresa Brieva, Antonio Rivero, Antonio Rivero-Juarez
The fixed-dose combination therapy of sofosbuvir (SOF) plus velpatasvir (VEL) is the first pangenotypic, direct-acting antiviral (DAA), single-treatment regimen (STR) for the treatment of hepatitis C virus (HCV) infection to be commercialized. It is approved for the treatment of HCV genotypes 1, 2, 3, 4, 5, and 6. Following approval in 2016, new pharmacokinetic and pharmacodynamic data were reported, which led to important clinical applications. Areas covered: This review provides a summary of the pharmacokinetics, pharmacodynamics, efficacy and safety of SOF/VEL therapy for treatment of HCV infection...
February 6, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28165585/hepatitis-c-virus-infection-in-maintenance-hemodialysis-patients-recommendations-for-diagnostics-and-treatment
#20
Pavlina Dzekova-Vidimliski, Aleksandar Sikole
Hepatitis C virus (HCV) infection is highly prevalent among patients treated with maintenance hemodialysis and is an important cause of morbidity and mortality. It is necessary to determine the HCV genotype and the viral load to monitor the clinical and laboratory features and to establish an optimal antiviral treatment strategy. Antiviral treatments are presented with a standard interferon-based regimen and new direct-acting antiviral agents. The advent of direct-acting antivirals has improved the efficacy and safety of HCV treatment for most patients, even in difficult-to-treat populations such as patients on hemodialysis...
February 1, 2017: International Journal of Artificial Organs
keyword
keyword
36135
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"